Drug intelligence / Profile preview

TTX-CRISPR

Development stage: Unknown
Lead developer: TransCode Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies

Overview

TTX-CRISPR is a gene transference therapy developed using TransCode Therapeutics' proprietary TTX platform, which enables systemic delivery of targeted nucleic acid-based therapeutics, specifically incorporating CRISPR-derived technology, to tumors for cancer treatment. It represents an early-stage investigational candidate aimed at leveraging CRISPR for oncological applications, potentially through gene editing or related mechanisms to address tumor biology. The program emerged from a collaboration with BRAIN Biotech to advance this CRISPR-derived platform, though specific details on its exact editing target, payload, or delivery method beyond the TTX nanoparticle system remain limited in public disclosures.

Beyond the preview

Go deeper on TTX-CRISPR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTX-CRISPR.

Explore the full profile